Altimmune, Inc.（ALT）財務資料ALTAltimmune, Inc.

Evaluating the bottom line, Altimmune, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.87%, provide a clear picture of how effectively ALT converts its operational activities into shareholder value.

In the context of the broader market, ALT competes directly with industry leaders such as PRTA and CBIO. With a market capitalization of $427.94M, it holds a significant position in the sector. When comparing efficiency, ALT's gross margin of N/A stands against PRTA's 100.00% and CBIO's 100.00%. Such benchmarking helps identify whether Altimmune, Inc. is trading at a premium or discount relative to its financial performance.

Altimmune has reported consistent losses, with a net income loss of $22,825,000 in Q2 2026 and a forward P/E of 8.18, indicating potential undervaluation but also uncertainty in profitability. Gross margins are currently at 0% for the upcoming quarters, reflecting a lack of revenue generation.